Clinical trials: GFAP
Multiple Sclerosis
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
Serum neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) measured by single molecule array (SIMOA) are novel biomarkers of multiple sclerosis patients (MS) activity and progression.
- Trial name
- Nf-Ella Loca (NCT05352971)
- Testing
- Biomarker quantification
- Where
- 10 sites in France
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes